Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025506 | 0.92 | NAMPT (0.57) | NAMPTLMNAALDH1A1 | |
| SCHEMBL14025660 | 0.89 | AKR1C3 (0.53) | NAMPTMEN1KMT2AAKR1C3LMNA | |
| SCHEMBL14025496 | 0.89 | NAMPT (0.70) | NAMPTMEN1KMT2AAKR1C3LMNA | |
| SCHEMBL14025487 | 0.89 | KMT2A (0.69) | NAMPTMEN1KMT2AAKR1C3LMNA | |
| SCHEMBL4787008 | 0.83 | NAMPT (0.55) | NAMPTMEN1KMT2AAKR1C3LMNA | |
| SCHEMBL14025524 | 0.82 | NAMPT (0.52) | NAMPTMEN1KMT2AAKR1C3LMNA | |
| SCHEMBL14025685 | 0.81 | NAMPT (0.52) | NAMPTAKR1C3LMNAALDH1A1TSHR | |
| SCHEMBL14025661 | 0.80 | AKR1C3 (0.62) | NAMPTMEN1KMT2AAKR1C3SMN1; SMN2 | |
| SCHEMBL14025485 | 0.80 | NAMPT (0.52) | NAMPTMEN1KMT2AAKR1C3LMNA | |
| SCHEMBL14025505 | 0.80 | NAMPT (0.67) | NAMPTMEN1KMT2AAKR1C3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | NAMPT 513/4885MEN1 173/4885KMT2A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.